Published in Translational Psychiatry, the study by Yoo, Zhang, Mandal and colleagues focuses on Scn2a-deficient mice. The human SCN2A gene encodes NaV1.2, a voltage-gated sodium channel concentrated at neuronal membranes. These channels help nerve cells generate and transmit electrical impulses, allowing information to travel through neural circuits. Variants that impair SCN2A function have been associated with developmental delay, intellectual disability and autism-related traits, while other variants can increase neuronal excitability and contribute to epilepsy. The gene therefore sits at a critical junction between electrical signaling and brain development.

To investigate the consequences of Scn2a deficiency, the researchers used single-nucleus RNA sequencing, a method that profiles gene activity in individual cell nuclei. Instead of measuring an average signal from an entire piece of brain tissue, the technique separates molecular information from thousands of nuclei and assigns each nucleus to a particular cell type or cellular state. This distinction is crucial in the brain, where neurons, astrocytes, oligodendrocytes, microglia and other cells perform different functions and may respond differently to the same genetic change.

The resulting molecular map revealed disrupted transcriptional programs in the prefrontal cortex. Transcriptional programs are coordinated sets of genes that become active together to support processes such as synaptic communication, energy production, structural maintenance and immune signaling. When these programs are altered, the effect can extend far beyond the protein directly encoded by the mutated gene. In Scn2a-deficient animals, the study indicates that loss of normal sodium-channel function is associated with broader changes in the molecular machinery that sustains neural circuits.

One important implication is that the impact of Scn2a deficiency may not be confined to the electrical properties of neurons. Neurons rely on precisely regulated gene networks to build synapses, transport materials along their processes, respond to incoming signals and maintain stable levels of excitation. Disruption in these systems can weaken communication between cells or disturb the balance between excitation and inhibition. That balance is essential: excessive excitation can destabilize circuits, while insufficient activity can interfere with learning, development and adaptive behavior.

The single-nucleus approach also allows researchers to distinguish changes that occur in specific populations of cells. A gene-expression shift in excitatory neurons may have a different meaning from a similar shift in inhibitory interneurons or glial cells. Glial cells, once regarded mainly as support cells, regulate neurotransmitter levels, provide metabolic assistance, shape synapses and participate in inflammatory responses. By examining these populations separately, the study provides a more refined picture of how Scn2a deficiency may alter communication among the diverse cellular communities that make up the prefrontal cortex.

The prefrontal cortex is especially relevant to conditions associated with SCN2A mutations because it develops over an extended period and depends on carefully timed interactions between neurons and supporting cells. Its circuits integrate sensory information, regulate behavior and coordinate responses to changing circumstances. Molecular disturbances in this region could therefore have consequences that emerge across multiple domains, including cognition, social interaction and behavioral flexibility. The mouse findings do not directly reproduce human disease, but they identify biological processes that can now be tested in additional models and patient-derived cells.

By revealing disrupted pathways rather than focusing only on one gene, the research may also help explain why SCN2A-related disorders show such diverse clinical features. The same gene can contribute to very different outcomes depending on the exact mutation, developmental stage, cell type affected and surrounding genetic environment. A pathway-level view could help scientists determine which molecular changes are shared across patients and which are specific to particular forms of SCN2A dysfunction. In the longer term, that information could support more precisely targeted treatments.

The study does not mean that a single molecular signature can predict behavior or provide an immediate therapy. Further work will be needed to confirm which transcriptional changes directly alter neural function, determine when they arise, and establish whether they can be reversed. Nevertheless, the findings demonstrate the power of single-nucleus transcriptomics to expose hidden cellular effects of gene loss. As researchers continue mapping the brain one cell at a time, studies such as this are transforming genetic clues into mechanistic explanations for neurodevelopmental disorders—and bringing scientists closer to interventions designed around the biology of individual circuits.

Subject of Research: Scn2a deficiency and disrupted molecular pathways in the prefrontal cortex of mice

Article Title: Single-nucleus transcriptomics reveals disrupted pathways in the prefrontal cortex of Scn2a-deficient mice

Article References: Yoo, YE., Zhang, Z., Mandal, P. et al. “Single-nucleus transcriptomics reveals disrupted pathways in the prefrontal cortex of Scn2a-deficient mice.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04348-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04348-0

Keywords: SCN2A, Scn2a deficiency, single-nucleus transcriptomics, prefrontal cortex, neurodevelopmental disorders, autism, epilepsy, gene expression, neuronal circuits, mouse model

Arousal represents a fundamental neurophysiological process essential for survival, enabling organisms to respond to external and internal stimuli with appropriate behavioral and neural adaptations. This highly conserved mechanism across species ensures a meticulously balanced state, modulating responsiveness between lethargy and sensory hypersensitivity. Dysregulation of this balance manifests clinically as either diminished responsiveness or excessive wakefulness and sensory overload, typical hallmarks of stress and various neurodevelopmental pathologies.

Fundamental to this regulatory system is the diversity of proteins synthesized during development and adulthood through alternative splicing—a sophisticated post-transcriptional gene editing process. Alternative splicing enables the generation of multiple functionally distinct protein isoforms from a single gene, often mediated by the inclusion or exclusion of microexons. Microexons are exceptionally short exonic sequences within neuronal genes that profoundly influence protein function and neuronal circuit dynamics despite their minuscule size.

The investigative team employed zebrafish larvae, leveraging their optical transparency and genetic tractability to scrutinize the behavioral consequences of neural microexon misregulation. Larvae exhibiting abnormal microexon patterns demonstrated conspicuous hyperarousal behaviors including disrupted swim patterns and shortened sleep duration. “These larvae not only sleep less frequently but also take considerably longer to initiate sleep,” remarks first author Tahnee Mackensen. This behavioral hyperactivity parallels neural hyperexcitability, suggesting microexon regulation as a pivotal determinant of neurobehavioral states.

At the cellular signaling level, the researchers identified dysregulated cyclic adenosine monophosphate (cAMP) cascades as a key mediator of the observed hyperactive state. cAMP is a ubiquitous second messenger involved in modulating neuronal excitability and synaptic plasticity. The altered splicing of microexons modulates cAMP synthesis and degradation pathways, leading to an aberrant excitation of forebrain neurons in hyperaroused larvae. Notably, this altered cAMP signaling manifests as heightened cAMP-dependent protein kinase A (PKA) activity and subsequent phosphorylation of the transcription factor CREB, implicating the canonical cAMP-PKA-CREB pathway in the regulation of arousal.

The study’s pharmacological interventions underscore the centrality of cAMP regulation in arousal control. Application of cAMP inhibitors normalized the elevated neural activity and behavioral hyperarousal in mutant fish, whereas artificially elevating cAMP in wild-type fish recapitulated the hyperactive phenotype. This bidirectional modulation fortifies the concept that neuronal cAMP levels function as a ‘thermostat’ for arousal states, fine-tuning neuronal excitability and behavioral responsiveness.

Beyond the immediate findings in zebrafish, this research builds upon prior observations in drosophila models demonstrating that microexon disruption similarly impairs sleep and elevates arousal. “The parallel between species indicates an evolutionarily conserved arousal mechanism,” explains Manuel Irimia, senior author. This conservation implies that microexon misregulation, while mechanistically nuanced, may contribute to the neuropsychiatric symptomatology observed in mammals, including humans.

Human neurological disorders such as autism and schizophrenia are often accompanied by sleep disruption and sensory processing anomalies attributed, in part, to aberrant microexon splicing. While microexon alterations are unlikely to be sole causative factors, they may exacerbate or modulate disease phenotypes by disturbing neural excitability homeostasis. These insights prompt a reevaluation of therapeutic strategies aimed at restoring microexon splicing fidelity or modulating cAMP signaling pathways to alleviate neurodevelopmental symptomatology.

Moreover, the link between this microexon-cAMP pathway and mood disorders such as anxiety and depression opens compelling avenues for future research. The cAMP-PKA-CREB axis has well-documented roles in synaptic plasticity and mood regulation, suggesting that microexon-associated dysregulation could contribute to broader neuropsychiatric conditions. “This discovery might just scratch the surface of a complex regulatory network influencing brain function,” notes Mackensen.

The transparency and genetic accessibility of the zebrafish model provided unparalleled opportunities to visualize and quantify internal states through behavioral readouts. Advanced imaging of larval swimming patterns and direct measurement of neurochemical parameters furnished robust correlative evidence linking genetic alterations to functional outcomes. These technical advancements highlight the integrative power of model organisms in neuroscience.

Importantly, this research received support from an array of prestigious funding bodies, including the Horizon 2020 Framework Programme, the Marie Sklodowska-Curie Actions, and the Wellcome Trust, emphasizing the global significance and collaborative nature of this work. The study’s publication in Science Advances confirms its high impact and relevance to the scientific community.

As the team pursues translational studies, the prospect of correcting arousal imbalances by manipulating cAMP pathways or restoring microexon expression presents a promising frontier. This is especially critical given that aberrant arousal and sleep disturbances profoundly impair quality of life in neurodevelopmental disorders. The findings pave the way for multidisciplinary approaches integrating molecular genetics, neurobiology, and pharmacology to develop targeted interventions.

In summation, the identification of neuronal microexons as key modulators of arousal states via the cAMP-PKA-CREB pathway in zebrafish represents a seminal advance in our understanding of the molecular substrates governing complex behavioral phenotypes. This research not only deciphers fundamental biological mechanisms but also holds translational potential to inform therapeutic avenues for neuropsychiatric conditions marked by disrupted arousal and sleep.

Subject of Research: Animals

Article Title: Neuronal microexons modulate arousal via the cAMP-PKA-CREB pathway in zebrafish

News Publication Date: 19-Jun-2026

Web References: 10.1126/sciadv.ady8291

Image Credits: UPF – CRG

Keywords: Exons, Gene splicing, Developmental neuroscience, Anxiety, Sleep disorders, cAMP signaling, Zebrafish

Neurodevelopmental disorders constitute a broad spectrum of conditions with heterogeneous genetic etiologies, posing considerable challenges to diagnosis and treatment. The crux of this new investigation lies in deciphering whether genes implicated in these disorders converge on shared molecular pathways and neurobiological processes during brain development. Utilizing cutting-edge RNA sequencing and functional assays, the authors analyzed a cohort of NDD-associated genes across neuronal cultures and animal brains, identifying common transcriptomic signatures that herald convergent disease mechanisms.

One of the remarkable aspects of this work is its dual-pronged approach: combining in vitro cultured neurons with in vivo animal models to validate findings across systems. In vitro, patient-derived neurons carrying mutations in distinct risk genes revealed overlapping patterns of dysregulated gene expression enriched for synaptic function, neuronal differentiation, and chromatin remodeling. These alterations were mirrored in vivo within mouse models engineered to harbor analogous genetic lesions, reinforcing the physiological relevance of the observed transcriptomic convergence.

The study employed state-of-the-art single-cell RNA sequencing to profile thousands of individual neurons, teasing apart subtle shifts in gene expression landscapes induced by diverse pathogenic mutations. This high-resolution data uncovered signatures indicative of disrupted excitatory-inhibitory balance, which is a hallmark of many NDDs. Such findings illuminate how genetically heterogeneous causes can lead to a common neurobiological phenotype, thereby explaining shared clinical features across different disorders.

Beyond molecular perturbations, the research eloquently bridges genotype to phenotype by documenting convergent morphological and functional abnormalities. Neuronal cultures from various mutant lines displayed common deficits in dendritic arborization and synaptic connectivity, key determinants of neural circuit formation. In parallel, electrophysiological assessments demonstrated consistent impairments in synaptic transmission and network dynamics, underscoring a unified pathophysiological basis for symptom manifestation.

Importantly, the convergent gene sets identified were enriched for genes regulating crucial developmental processes such as synaptogenesis, neurotransmitter release, and chromatin accessibility. This implicates disruptions in finely tuned epigenetic and synaptic mechanisms as core drivers of NDD pathogenesis. The integration of transcriptomic data with functional outcomes thus paints a holistic picture of how diverse mutations funnel into common neural developmental derailments.

The translational implications of these findings are profound. Recognizing convergence at the transcriptional and phenotypic levels suggests that therapeutic strategies targeting shared molecular pathways might transcend individual genetic diagnoses. This could accelerate the development of broad-spectrum interventions, moving beyond the traditional one-gene-one-therapy paradigm that has thus far limited clinical progress.

Moreover, this study exemplifies the power of combining multi-modal experimental systems to elucidate complex brain disorders. The synergy between in vitro human-derived neurons and genetically defined animal models offers a robust platform to dissect disease mechanisms and test potential therapeutics. As precision medicine evolves, such integrative approaches will be indispensable in bridging molecular insights with clinical application.

The researchers also highlighted intriguing nuances, such as context-dependent gene regulation and cell-type specificity, which may fine-tune the phenotypic impacts of risk genes. Future work dissecting these layers promises to further refine our understanding of NDD heterogeneity and resilience factors, ultimately informing personalized intervention strategies.

Notably, this research dovetails with emerging evidence implicating shared molecular networks across varied neuropsychiatric conditions, suggesting a broader principle whereby diverse genetic insults converge on limited, vulnerable biological circuits during development. Such paradigms could reshape the classification and treatment of neurodevelopmental and psychiatric illnesses alike.

In sum, this landmark study delineates a cohesive transcriptomic and phenotypic convergence among neurodevelopmental disorder risk genes, illuminating common pathogenic pathways. By unraveling how genetic diversity translates into neurological similarity, it lays a powerful foundation for next-generation diagnostics and therapeutics poised to improve the lives of millions affected by these disabling conditions.

As the field progresses, leveraging these insights to identify biomarkers and modulate convergent pathways will be critical in transforming molecular discoveries into tangible clinical benefits. This research heralds a new era in understanding the molecular convergence of neurodevelopmental disorders and opens new avenues for combating some of the most challenging brain diseases of our time.

Subject of Research: Neurodevelopmental disorder risk gene convergence at transcriptomic and phenotypic levels

Article Title: Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo

Article References:
Fernandez Garcia, M., Retallick-Townsley, K., Pruitt, A. et al. Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02247-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02247-7